CSIMarket
 


Eterna Therapeutics Inc   (ERNA)
Other Ticker:  
 

Eterna Therapeutics Inc 's Leverage Ratio

ERNA's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -6%, in IV Quarter 2023 ,Leverage Ratio deteriorated to 20.01 reached a new all-time high.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 155 other companies have achieved lower Leverage Ratio than Eterna Therapeutics Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 2395, from total ranking in the third quarter 2023 at 2643 .

Explain Leverage Ratio?
Who are ERNA Customers?
What are ERNA´s Total Liabilities?


ERNA Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -81.56 % -59.58 % -73.84 % -57.37 % -52.53 %
Y / Y Total Liabilities Change 339.27 % 292.45 % 363.31 % -54.27 % 81.77 %
Leverage Ratio MRQ 20.01 13.35 11.15 1.05 0.84
ERNA's Total Ranking # 2395 # 2643 # 3406 # 1424 # 1617
Seq. Equity Change -37.31 % -7.86 % -47.62 % -39.04 % 37.38 %
Seq. Total Liabilities Change -6 % 10.33 % 457.56 % -24.03 % -16.02 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 156
Healthcare Sector # 375
Overall Market # 2395


Leverage Ratio Statistics
High Average Low
20.01 2.65 0.22
(Dec 31 2023)  




Financial Statements
Eterna Therapeutics Inc 's Equity $ 2 Millions Visit ERNA's Balance sheet
Eterna Therapeutics Inc 's Total Liabilities $ 45 Millions Visit ERNA's Balance sheet
Source of ERNA's Sales Visit ERNA's Sales by Geography


Cumulative Eterna Therapeutics Inc 's Leverage Ratio

ERNA's Leverage Ratio for the trailling 12 Months

ERNA Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -81.56 % -59.58 % -73.84 % -57.37 % -52.53 %
Y / Y Total Liabilities TTM Growth 339.27 % 292.45 % 363.31 % -54.27 % 81.77 %
Leverage Ratio TTM 8.39 4.03 2.27 0.91 0.91
Total Ranking TTM # 2404 # 3229 # 2931 # 1876 # 2206
Seq. Equity TTM Growth -37.31 % -7.86 % -47.62 % -39.04 % 37.38 %
Seq. Total Liabilities TTM Growth -6 % 10.33 % 457.56 % -24.03 % -16.02 %


On the trailing twelve months basis Despite of the repayements of liabilities of -6% in the trailing twelve months ending in IV Quarter 2023, Leverage Ratio improved to 8.39, above Eterna Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 16, during the past 12 months, other companies have achieved lower Leverage Ratio than Eterna Therapeutics Inc . While Leverage Ratio total ranking has improved so far to 2558, from total ranking in previous 12 month period at 34.

Explain Leverage Ratio?
Who are ERNA Customers?
What are ERNA´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 29
Within the Market # 2395


trailing twelve months Leverage Ratio Statistics
High Average Low
8.59 2.05 0.66
(Dec 31 2023)   (March 31, 2014)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Morphosys Ag  40.31 $ 2,214.533  Millions$ 54.935  Millions
Lucy Scientific Discovery Inc   38.57 $ 3.130  Millions$ 0.081  Millions
Nascent Biotech Inc  20.05 $ 0.609  Millions$ 0.030  Millions
Eterna Therapeutics Inc   20.01 $ 44.683  Millions$ 2.233  Millions
Gri Bio Inc   10.41 $ 2.697  Millions$ 0.259  Millions
Abbvie inc   8.66 $ 90,072.000  Millions$ 10,397.000  Millions
Blueprint Medicines Corporation  7.03 $ 918.641  Millions$ 130.609  Millions
Ionis Pharmaceuticals Inc  6.73 $ 2,603.386  Millions$ 386.686  Millions
Bio path Holdings inc   6.30 $ 2.779  Millions$ 0.441  Millions
Mersana Therapeutics Inc   5.13 $ 189.156  Millions$ 36.904  Millions
Biofrontera Inc   4.83 $ 23.139  Millions$ 4.793  Millions
Collegium Pharmaceutical Inc   4.82 $ 941.753  Millions$ 195.431  Millions
Eli Lilly And Company  4.69 $ 50,993.800  Millions$ 10,863.700  Millions

Date modified: 2024-03-15T06:32:05+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com